The drug that Equillium licensed from India-based pharma giant Biocon has received authorization for emergency use in that country in patients hospitalized with COVID-19.
The treatment, itolizumab, reduced mortality in a 30-person open-label randomized controlled trial in which the goal was... Read more »
A Blueprint Medicines cancer drug candidate currently under FDA review will have the marketing muscle of Roche behind it if it wins regulatory approval.
The two companies are partnering on the drug, pralsetinib, a targeted cancer therapy developed for lung and... Read more »
Have you had your say yet? The 2020 National Xconomy Awards represent the very best our life science industry has to offer. It is our privilege to recognize emerging companies and technologies, highlight groundbreaking business collaborations and strategies, celebrate corporate responsibility... Read more »
Miss Xconomy’s Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health event or want to revisit the insightful content? Our new podcast and special report package the highlights for you.
Listen to the podcast or download the report today.
The podcast includes expert... Read more »
At the year’s start Thousand Oaks, CA-based Amgen closed a strategic collaboration with BeiGene, investing $2.8 billion to gain a presence in what’s becoming an ever-more essential market for global drug development. The investment earned it an R&D pact and ownership... Read more »
Three biotech companies collectively raised $584 million in their initial public offerings last week, continuing a streak that has the healthcare sector playing a leading role in the robust level of market activity this summer.
Of the three companies, the one... Read more »
Cash flowed throughout the life sciences ecosystem this week as Blackstone (NYSE: BX) raised a record-setting life sciences fund, companies of all stages announced new financings, and money continued to find its way to those working on efforts to treat... Read more »
Kymera Therapeutics has signed a deal with French biopharma Sanofi to advance two potential treatments for immune-inflammatory diseases that leverage the Cambridge, MA-based company’s research into protein degradation, the natural mechanism cells use to get rid of unwanted proteins.
Drug developers... Read more »
The first drug for neurofibromatosis type 1 (NF1) is available to patients following the FDA’s approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection Therapeutics is vying to be runner-up, but its founders say they can eventually win out... Read more »
Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company’s goal of developing targeted therapies based... Read more »
By early September Biogen—plus the many scientists, patients, and investors following the saga of its controversial Alzheimer’s drug aducanamab—should know whether the FDA plans to review the Cambridge, MA biotech’s experimental brain disease treatment.
The company announced Wednesday that its submission... Read more »
The 2020 National Xconomy Awards – celebrating the best in biotech innovation and entrepreneurship – just got bigger!
We’re excited to announce the expansion of the 2020 National Xconomy Awards. Presented in a digital format, the 2020... Read more »
One way that a cell regulates which genes in its DNA are expressed and when is by altering the structure of the fibers that are formed by the genetic material and associated proteins, packaging that’s referred to as chromatin.
Foghorn Therapeutics,... Read more »